Literature DB >> 22925968

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Christian Klein1, Claudio Sustmann, Markus Thomas, Kay Stubenrauch, Rebecca Croasdale, Jürgen Schanzer, Ulrich Brinkmann, Hubert Kettenberger, Jörg T Regula, Wolfgang Schaefer.   

Abstract

The development of bispecific antibodies has attracted substantial interest, and many different formats have been described. Those specifically containing an Fc part are mostly tetravalent, such as stabilized IgG-scFv fusions or dual-variable domain (DVD) IgGs. However, although they exhibit IgG-like properties and technical developability, these formats differ in size and geometry from classical IgG antibodies. Thus, considerable efforts focus on bispecific heterodimeric IgG antibodies that more closely mimic natural IgG molecules. The inherent chain association problem encountered when producing bispecific heterodimeric IgG antibodies can be overcome by several methods. While technologies like knobs-into-holes (KiH) combined with a common light chain or the CrossMab technology enforce the correct chain association, other approaches, e.g., the dual-acting Fab (DAF) IgGs, do not rely on a heterodimeric Fc part. This review discusses the state of the art in bispecific heterodimeric IgG antibodies, with an emphasis on recent progress.

Entities:  

Keywords:  CrossMab; DAF; antibody; bispecific; heavy chain; heterodimerization; knobs-into-holes; light chain

Mesh:

Substances:

Year:  2012        PMID: 22925968      PMCID: PMC3502232          DOI: 10.4161/mabs.21379

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  59 in total

Review 1.  Bispecific human IgG by design.

Authors:  P Carter
Journal:  J Immunol Methods       Date:  2001-02-01       Impact factor: 2.303

2.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 3.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Authors:  Mosmi Surati; Premal Patel; Amy Peterson; Ravi Salgia
Journal:  Expert Opin Biol Ther       Date:  2011-12       Impact factor: 4.388

4.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 5.  Smarter drugs: a focus on pan-specific monoclonal antibodies.

Authors:  Séverine Fagète; Nicolas Fischer
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

6.  Absence of preferential homologous H/L chain association in hybrid hybridomas.

Authors:  W B De Lau; K Heije; J J Neefjes; M Oosterwegel; E Rozemuller; B J Bast
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

7.  Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

Authors:  Charlotte F McDonagh; Alexandra Huhalov; Brian D Harms; Sharlene Adams; Violette Paragas; Shinji Oyama; Bo Zhang; Lia Luus; Ryan Overland; Stephanie Nguyen; Jinming Gu; Neeraj Kohli; Matt Wallace; Michael J Feldhaus; Arthur J Kudla; Birgit Schoeberl; Ulrik B Nielsen
Journal:  Mol Cancer Ther       Date:  2012-01-16       Impact factor: 6.261

8.  Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry.

Authors:  Séverine Fagète; François Rousseau; Giovanni Magistrelli; Franck Gueneau; Ulla Ravn; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  J Biol Chem       Date:  2011-10-31       Impact factor: 5.157

9.  Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.

Authors:  Pavel Strop; Wei-Hsien Ho; Leila M Boustany; Yasmina N Abdiche; Kevin C Lindquist; Santiago E Farias; Mathias Rickert; Charles Takeshi Appah; Edward Pascua; Teresa Radcliffe; Janette Sutton; Javier Chaparro-Riggers; Wei Chen; Meritxell Galindo Casas; Sherman Michael Chin; Oi Kwan Wong; Shu-Hui Liu; German Vergara; Dave Shelton; Arvind Rajpal; Jaume Pons
Journal:  J Mol Biol       Date:  2012-04-25       Impact factor: 5.469

Review 10.  Hybrid antibodies in cancer diagnosis and therapy.

Authors:  S Ménard; S Canevari; M I Colnaghi
Journal:  Int J Biol Markers       Date:  1989 Jul-Sep       Impact factor: 3.248

View more
  69 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

2.  Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.

Authors:  Wolfgang Schaefer; Hans R Völger; Stefan Lorenz; Sabine Imhof-Jung; Jörg T Regula; Christian Klein; Michael Mølhøj
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

3.  Electrostatic engineering of the interface between heavy and light chains promotes antibody Fab fragment production.

Authors:  Yuki Ohmuro-Matsuyama; Keita Mori; Hirotsugu Hamada; Hiroshi Ueda; Hideki Yamaji
Journal:  Cytotechnology       Date:  2016-02-08       Impact factor: 2.058

Review 4.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

5.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

6.  Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.

Authors:  Chen Chen; Tetsuya Wakabayashi; Masaru Muraoka; Feng Shu; Chia Wei Shan; Chong Chor Kun; Ching Tim Jang; Ishin Soehano; Yuichiro Shimizu; Tomoyuki Igawa; Jun-Ichi Nezu
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

7.  Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.

Authors:  Nazzareno Dimasi; Ryan Fleming; Kris F Sachsenmeier; Binyam Bezabeh; Carl Hay; Jincheng Wu; Erin Sult; Saravanan Rajan; Li Zhuang; Peter Cariuk; Andrew Buchanan; Michael A Bowen; Herren Wu; Changshou Gao
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

8.  A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Authors:  Juergen M Schanzer; Katharina Wartha; Rebecca Croasdale; Samuel Moser; Klaus-Peter Künkele; Carola Ries; Werner Scheuer; Harald Duerr; Sandra Pompiati; Jan Pollman; Jan Stracke; Wilma Lau; Stefan Ries; Ulrich Brinkmann; Christian Klein; Pablo Umana
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

9.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.